The present invention provides an artificial dressing and a use of the artificial dressing for promoting wound healing. The artificial dressing includes a gelatin and a fungal extract.

To provide a liquid medical material maintaining a colloid in a more sol form than a solid at normal temperature, having a higher function as a wound dressing material and a hemostatic material than fibrin glue, and being able to be produced safely and inexpensively. A gelatin aqueous solution including calcium at a concentration of 0.2 M or more and 1.0 M or less, and having a concentration of 5% by weight or more and 40% by weight or less, an average molecular weight of 80,000 or more and 120,000 or less, and a molecular weight distribution of 20,000 or more and 300,000 or less, and transglutaminase inducing crosslinking of the gelatin, are included. It is preferable that the calcium has a concentration of 0.2 M or more and 0.7 M or less, the gelatin has a bloom of 160 or more and 250 or less, and the transglutaminase has activity per unit of 36 U/ml to 400 U/ml.

A surgical sealant comprising a first agent containing a hydrophobically-modified gelatin derived from a cold-water fish, and a second agent containing a water-soluble molecule for crosslinking, wherein the water-soluble molecule for crosslinking is at least one kind selected from the group consisting of poly acids and acid anhydrides having two or more active ester groups, and aldehyde compounds having two or more aldehyde groups, the hydrophobically-modified gelatin derived from a cold-water fish is a gelatin in which at least a part of amino groups of side chains of a gelatin derived from a cold-water fish has been substituted by hydrophobic groups, and the hydrophobic groups are linear chain aliphatic groups each having 8 to 18 carbon atoms, with a substitution rate (number of moles of hydrophobic groups/(total number of moles of hydrophobic groups and reactive amino groups in gelatin)100) of 3 to 20 mol %.

Compositions for enhancing wound healing are disclosed herein. Also disclosed are methods of making the compositions and methods of using the compositions for the prevention of biofilm formation and for the inhibition of pathogen growth and proliferation.

Hemostatic powders are synergistically used in conjunction with self-assembling peptide hydrogels to promote hemostasis at a target site. Related methods, kits, and devices for hemostasis are disclosed.

A wound dressing material includes a particle having a crosslinked gelatin derivative, the gelatin derivative having the structure represented by the following formula (1):
GltnNHCHR.sup.1R.sup.2(1)
wherein Gltn represents a gelatin residue, R.sup.1 represents an alkyl group having 1-17 carbon atoms, and R.sup.2 represents a hydrogen atom or an alkyl group having 1-17 carbon atoms, and the particle having a particle size ranging from 1 to 1,000 ?m.

A hemostatic material, a preparation method thereof, and a pharmaceutical composition containing the same are introduced. The hemostatic material includes 200 to 1600 parts by weight of water-insoluble gelatin and 100 to 1000 parts by weight of hydrating material. The preparation method for the hemostatic material includes the steps of (a) providing 200 to 1600 parts by weight of water-insoluble gelatin and 100 to 1000 parts by weight of hydrating material; and (b) combining the water-insoluble gelatin with the hydrating material to form a hemostatic material. The pharmaceutical composition includes an aforementioned hemostatic material and active pharmaceutical ingredients. Through the aforementioned hemostatic material, hemostatic products can increase the blood absorption capacity.

A foam biomaterial is disclosed. The foam biomaterial includes a biomaterial ink having an interconnected pore structure. The foam biomaterial can have a porosity from about 10% to about 90%. Systems and methods for forming and depositing the foam biomaterial are also disclosed. In exemplary applications, the foam biomaterial can be deposited on or within a body of a subject or patient.

The present invention is directed to a hemostatic semi-solid paste material comprising a bioabsorbable carrier hemostatic material; and a supplemental hemostatic agent; wherein the paste material has an elongated form extending along a lengthwise axis with an aspect ratio of at least 3; wherein the paste is self-supporting and syringe extrudable; and wherein the supplemental hemostatic agent has a non-homogenous distribution profile across a cross-section taken across the lengthwise axis. In another aspect, the present invention relates to devices for forming and expressing the hemostatic material.

The adhesive includes a first agent that includes a gelatin derivative in which a hydrophobic group is bound to gelatin through an imino group represented by a formula 1: GltnNH-R.sup.1 and includes cyclodextrin; and a second agent that includes a crosslinking agent for the gelatin derivative. The cured product is resistant to swell in a physiological saline solution. In the formula 1, Gltn represents a residue of the gelatin, R.sup.1 represents the hydrophobic group, and NH represents the imino group binding to the residue and the hydrophobic group.